Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 9,126 matching trials from the live ClinicalTrials.gov search.

Filters: Tampa, Florida Clear all

Conditions: Migraine
Interventions: Eptinezumab; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 20
States / cities: New Haven, Connecticut • Stamford, Connecticut • Gainesville, Florida + 17 more

Conditions: Nonsmall Cell Lung Cancer, Nonsmall Cell Lung Cancer, Stage II, Nonsmall Cell Lung Cancer Stage III, Unresectable Non-Small Cell Lung Carcinoma
Interventions: Genomically Guided Radiation Therapy (RT); Radiation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Inflammatory Bowel Disease (IBD), Anemia, Inflammatory Bowel Disease (IBD); Anemia
Interventions: DISC-0974, Placebo; Drug
Lead sponsor: Disc Medicine, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 15
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 10 more

Conditions: Alopecia Areata(AA)
Interventions: HCW9302, an IL-2 fusion protein; Drug
Lead sponsor: HCW Biologics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Tampa, Florida • Indianapolis, Indiana • Columbus, Ohio

Conditions: Alzheimer's Disease
Interventions: Aducanumab (BIIB037), Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 1,653 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 59
States / cities: Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 52 more

Conditions: Epilepsy
Interventions: M106 VNS Therapy System; Device
Lead sponsor: Cyberonics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 15
States / cities: Phoenix, Arizona • Stanford, California • Tampa, Florida + 12 more

Conditions: Large B-cell Lymphoma
Interventions: cemacabtagene ansegedleucel, Fludarabine, Cyclophosphamide, Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™; Genetic · Drug · Device
Lead sponsor: Allogene Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 64
States / cities: Gilbert, Arizona • Hot Springs, Arkansas • Berkeley, California + 52 more

Conditions: HIV Infections
Interventions: Early Initiation of Highly Active Anti-Retroviral Therapy, Standard Care; Procedure
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 24 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 22
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 14 more

Conditions: Depression, Spinal Cord Injuries
Interventions: Acceptance and commitment therapy (ACT); Behavioral
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Hypertension
Interventions: metoprolol succinate; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 6 Years to 16 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 30
States / cities: Little Rock, Arkansas • Bellflower, California • Beverly Hills, California + 27 more

Conditions: Asthma
Interventions: fluticasone, montelukast, Fluticasone plus salmeterol; Drug
Lead sponsor: JHSPH Center for Clinical Trials; Other
Eligibility: 6 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 19
States / cities: Birmingham, Alabama • Denver, Colorado • Jacksonville, Florida + 16 more

Conditions: Asthma
Interventions: Formoterol Fumarate in the Pressair DPI, Low Dose, Formoterol Fumarate in the Pressair DPI, High Dose, Foradil Aerolizer, Low Dose, Foradil Aerolizer, High Dose, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 29
States / cities: Phoenix, Arizona • Encinitas, California • Los Angeles, California + 26 more

Conditions: Pmm2-CDG, Phosphomannomutase 2 Deficiency
Interventions: GLM101; Drug
Lead sponsor: Glycomine, Inc.; Industry
Eligibility: 2 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Tampa, Florida • Rochester, Minnesota

Conditions: Depressive Disorder, Major
Interventions: No Intervention; Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 18
States / cities: Birmingham, Alabama • Homewood, Alabama • California City, California + 15 more

Conditions: Hepatitis C, Chronic
Interventions: Not listed
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 65
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 53 more

Conditions: Lung Cancer
Interventions: ZD1839; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: NSCLC
Interventions: paclitaxel, paclitaxel poliglumex; Drug
Lead sponsor: CTI BioPharma; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 64
States / cities: Casa Grande, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 57 more

Conditions: Analgesic Drug Dependence, Colectomy
Interventions: Opioid Anesthesia, Opioid-free Anesthesia; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Differentiated Thyroid Cancer
Interventions: Cabozantinib, Placebo; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 16 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 31
States / cities: Newport Beach, California • Sacramento, California • San Francisco, California + 27 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Hydrolysed infant formula, Nonhydrolysed infant formula; Dietary Supplement
Lead sponsor: University of Helsinki; Other
Eligibility: Up to 7 Days
Enrollment: 5,156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2017
U.S. locations: 2
States / cities: Tampa, Florida • Pittsburgh, Pennsylvania

Conditions: PTSD
Interventions: TNX-102 SL; Drug
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 32
States / cities: Phoenix, Arizona • Rogers, Arkansas • Beverly Hills, California + 28 more

Conditions: Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Interventions: Icatibant, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 43
States / cities: La Jolla, California • Washington D.C., District of Columbia • Gainesville, Florida + 31 more

Conditions: Brain and Central Nervous System Tumors
Interventions: carmustine in ethanol, conventional surgery; Drug · Procedure
Lead sponsor: Direct Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 9 more

Conditions: Breast Cancer, Breast Cancer Female, Breast Cancer, Male, Invasive Breast Cancer, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, Stage II Breast Cancer, Stage III Breast Cancer
Interventions: Dendritic Cell Vaccine (DC1), Neoadjuvant Chemotherapy, Curative Surgery; Biological · Drug · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Search by objective public record fields.

A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC

Study of DISC-0974-201 in Participants With IBD and Anemia

HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata

221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

VNS Therapy Automatic Magnet Mode Outcomes Study in Epilepsy Patients Exhibiting Ictal Tachycardia (E-37)

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Preservation and Expansion of T-cell Subsets Following HAART De-intensification to Atazanavir/Ritonavir (ATV/r)

Acceptance and Commitment Therapy for Depressed People With Spinal Cord Injuries

307B - Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® in Hypertensive Pediatric Subjects

The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial

Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma

24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG

A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)

An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1

Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates

A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.

Opioid Free Anesthesia vs. Opioid Anesthesia Techniques.

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk

12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients

Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema

Carmustine in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer